BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Nov 19, 2007
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 11/16cls
Advanced Life (ADLS) Rodman Elemer Piros Price target Market outperform 4% $2.01
Piros raised his target to $6 from $4 after cethromycin met the primary endpoint of non-inferiority vs. Biaxin clarithromycin in the Phase III CL-05 trial to treat community-acquired pneumonia (CAP). ADLS received rights to the ketolide antibiotic from Abbott (ABT), which markets Biaxin (see B13). He also views ADLS as a strong potential acquisition candidate.
Ambrilia (TSX:AMB) Dundee David Martin Rating change Market outperform (from under review) -10% C$1.05
Martin set a C$2.90 target. He said the $18.7M raised in the recent follow-on reduces financial risk and provides the "much needed funds" to move AMB's pipeline forward. He expects data from the company's Phase III trial of its prolonged-release formulation of octreotide for acromegaly by mid-08, with EMEA and FDA submissions by YE08.
Applied Bio (ABI) JPMorgan Tycho Peterson Upgrade Overweight (from neutral) 1% $34.12
Peterson thinks ABI's SOLiD genetic analysis system for DNA sequencing will be "the most visible instrument...

Read the full 1021 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >